×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
EOLS – evolus, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
EOLS
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/17
08:48 am
eols
Evolus, Inc. (NASDAQ: EOLS) is now covered by analysts at BTIG Research. They set a "buy" rating and a $21.00 price target on the stock.
Low
Report
Evolus, Inc. (NASDAQ: EOLS) is now covered by analysts at BTIG Research. They set a "buy" rating and a $21.00 price target on the stock.
4/16
08:34 am
eols
Evolus Announces Commercial Launch of Evolysse™ [Yahoo! Finance]
Low
Report
Evolus Announces Commercial Launch of Evolysse™ [Yahoo! Finance]
4/16
08:00 am
eols
Evolus Announces Commercial Launch of Evolysse™
Low
Report
Evolus Announces Commercial Launch of Evolysse™
4/15
08:17 am
eols
Evolus Launches "Drop the F Word" Campaign in Advance of the Commercial Launch of Evolysse™ Injectable Hyaluronic Acid Gels [Yahoo! Finance]
Low
Report
Evolus Launches "Drop the F Word" Campaign in Advance of the Commercial Launch of Evolysse™ Injectable Hyaluronic Acid Gels [Yahoo! Finance]
4/15
08:00 am
eols
Evolus Launches “Drop the F Word” Campaign in Advance of the Commercial Launch of Evolysse™ Injectable Hyaluronic Acid Gels
Low
Report
Evolus Launches “Drop the F Word” Campaign in Advance of the Commercial Launch of Evolysse™ Injectable Hyaluronic Acid Gels
4/10
08:49 am
eols
Evolus, Inc. (NASDAQ: EOLS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $27.00 price target on the stock.
High
Report
Evolus, Inc. (NASDAQ: EOLS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $27.00 price target on the stock.
4/9
08:09 am
eols
Evolus, Inc. (NASDAQ: EOLS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $22.00 price target on the stock.
High
Report
Evolus, Inc. (NASDAQ: EOLS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $22.00 price target on the stock.
3/25
08:00 am
eols
Evolus to Participate in The Needham 24th Annual Virtual Healthcare Conference
Medium
Report
Evolus to Participate in The Needham 24th Annual Virtual Healthcare Conference
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/28
06:59 pm
eols
Form 4 Evolus, Inc. For: Mar 27 Filed by: MOATAZEDI DAVID
Low
Report
Form 4 Evolus, Inc. For: Mar 27 Filed by: MOATAZEDI DAVID
3/20
06:27 pm
eols
Form 4 Evolus, Inc. For: Mar 18 Filed by: Yamagishi-Dressler Tomoko
Low
Report
Form 4 Evolus, Inc. For: Mar 18 Filed by: Yamagishi-Dressler Tomoko
3/20
06:27 pm
eols
Form 4 Evolus, Inc. For: Mar 18 Filed by: MOATAZEDI DAVID
Low
Report
Form 4 Evolus, Inc. For: Mar 18 Filed by: MOATAZEDI DAVID
3/20
06:27 pm
eols
Form 4 Evolus, Inc. For: Mar 18 Filed by: Avelar Rui
Low
Report
Form 4 Evolus, Inc. For: Mar 18 Filed by: Avelar Rui
3/20
06:27 pm
eols
Form 4 Evolus, Inc. For: Mar 18 Filed by: Beaver Sandra
Low
Report
Form 4 Evolus, Inc. For: Mar 18 Filed by: Beaver Sandra
3/14
06:00 pm
eols
Form 4 Evolus, Inc. For: Mar 12 Filed by: Parschauer Karah Herdman
Low
Report
Form 4 Evolus, Inc. For: Mar 12 Filed by: Parschauer Karah Herdman
3/12
05:56 pm
eols
Form 144 Evolus, Inc. Filed by: Parschauer Karah Herdman
Low
Report
Form 144 Evolus, Inc. Filed by: Parschauer Karah Herdman
3/11
06:55 pm
eols
Form 4 Evolus, Inc. For: Mar 07 Filed by: Yamagishi-Dressler Tomoko
Medium
Report
Form 4 Evolus, Inc. For: Mar 07 Filed by: Yamagishi-Dressler Tomoko
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
6/4
Form 4/A Evolus, Inc. For: Jun 03 Filed by: Alphaeon Corp
16.7%
11/7 Evolus Announces Pricing of Public Offering of Common Stock 14.3%
7/17 Form 4 Evolus, Inc. For: Jul 15 Filed by: Parschauer Karah Herdman 11.6%
5/17 Form 424B4 Evolus, Inc. 8.0%
8/8 Juvly Aesthetics Continues Its Leadership Expansion with Appointment of a Chief People Officer 6.7%
2/25 Form 10-K Evolus, Inc. For: Dec 31 6.0%
5/21 ALPHAEON Corporation to Pay Off $88 million of Outstanding Third-Party Debt 5.4%
7/16 Form 8-K Evolus, Inc. For: Jul 15 4.8%
10/15 Evolus Inc (NASDAQ: EOLS) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. 4.4%
5/31 Form 4 Evolus, Inc. For: May 31 Filed by: SILVERNAIL LAUREN P 4.2%
11/7 Evolus Announces Pricing of Public Offering of Common Stock 14.3%
7/17 Form 4 Evolus, Inc. For: Jul 15 Filed by: Parschauer Karah Herdman 11.6%
5/17 Form 424B4 Evolus, Inc. 8.0%
8/8 Juvly Aesthetics Continues Its Leadership Expansion with Appointment of a Chief People Officer 6.7%
2/25 Form 10-K Evolus, Inc. For: Dec 31 6.0%
5/21 ALPHAEON Corporation to Pay Off $88 million of Outstanding Third-Party Debt 5.4%
7/16 Form 8-K Evolus, Inc. For: Jul 15 4.8%
10/15 Evolus Inc (NASDAQ: EOLS) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. 4.4%
5/31 Form 4 Evolus, Inc. For: May 31 Filed by: SILVERNAIL LAUREN P 4.2%
TOP News Decliners
5/15
ALPHAEON Corporation sells 4 million shares in Evolus Inc.
-11.2%
8/13 Evolus Inc (NASDAQ: EOLS) had its "outperform" rating re-affirmed by analysts at JMP Securities. They now have a $30.00 price target on the stock. -11.0%
3/17 Form DEF 14A Evolus, Inc. For: May 01 -10.7%
2/25 Q4/2019 12/31/2019 EPS -0.470 ZacksConsensus -0.850 ActVsEst 0.380 - Beat -8.6%
3/27 Evolus Inc (NASDAQ: EOLS) had its price target lowered by analysts at HC Wainwright from $31.00 to $16.00. They now have a "buy" rating on the stock. -8.0%
3/4 Evolus Provides Update on International Trade Commission (ITC) Case -7.7%
1/9 Form 8-K Evolus, Inc. For: Jan 09 -7.0%
1/10 Form 8-K Evolus, Inc. For: Jan 10 -6.8%
3/3 Evolus to Participate in Barclays 2020 Global Healthcare Conference -6.3%
8/12 Q2/2019 6/30/2019 EPS -1.370 ZacksConsensus -0.960 ActVsEst (0.410) - Miss -6.2%
8/13 Evolus Inc (NASDAQ: EOLS) had its "outperform" rating re-affirmed by analysts at JMP Securities. They now have a $30.00 price target on the stock. -11.0%
3/17 Form DEF 14A Evolus, Inc. For: May 01 -10.7%
2/25 Q4/2019 12/31/2019 EPS -0.470 ZacksConsensus -0.850 ActVsEst 0.380 - Beat -8.6%
3/27 Evolus Inc (NASDAQ: EOLS) had its price target lowered by analysts at HC Wainwright from $31.00 to $16.00. They now have a "buy" rating on the stock. -8.0%
3/4 Evolus Provides Update on International Trade Commission (ITC) Case -7.7%
1/9 Form 8-K Evolus, Inc. For: Jan 09 -7.0%
1/10 Form 8-K Evolus, Inc. For: Jan 10 -6.8%
3/3 Evolus to Participate in Barclays 2020 Global Healthcare Conference -6.3%
8/12 Q2/2019 6/30/2019 EPS -1.370 ZacksConsensus -0.960 ActVsEst (0.410) - Miss -6.2%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: